LOGO
LOGO

Puma Awaits Key Lung And Breast Cancer Trial Data For Aurora Kinase A Inhibitor In Q4

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
puma 30092025 lt

Breast cancer is the leading cause of cancer death among women worldwide, with about 3.2 million new cases and 1.1 million deaths expected by 2050, according to the WHO's International Agency for Research on Cancer. Up to 20% of breast cancer tumors overexpress HER2, a protein that promotes cell division and growth. Women with breast cancer that over-expresses HER2, referred to as HER2-positive breast cancer, are at greater risk for disease progression and death than women whose tumours do not over-express HER2.

The company we are profiling today is Puma Biotechnology Inc. (PBYI), the developer of breast cancer medicine Nerlynx.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

Latest Updates on COVID-19